Pharmaceuticals
AbbVie Climbs Earnings Beat, Guidance Boost
AbbVie climbs after beating first-quarter estimates and raising full-year guidance.
Bristol-Myers Squibb Expected to Earn $1.09 a Share
Bristol-Myers Squibb revenue expected to rise 10.8% to $5.8 billion.
AbbVie Expected to Earn $2.06 a share
AbbVie revenue expected to fall 2% to $7.8 billion.
CannTrust Shares Recover After Preliminary Quarterly Loss, New Share Issuance
Shares of Canadian cannabis-products maker CannTrust drop, then rebound, after the company reveals a preliminary quarterly loss and announces new share issuance.
A Tough Week for Biotech, the Candidates' Whipping Boy Again
Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.
Amgen: This Beaten Down Blue Chip Is Priced To Own
As the healthcare sector sells off, it's time to look for attractive value. You don't have to go any further than Amgen.
Danaher's Earnings Drop on GE Biopharma Acquisition Costs
Danaher reports first-quarter earnings that beat analysts' estimates though revises forward guidance on costs related to acquisition of GE's biopharma business.
Jim Cramer: Diversification Is Good for Offense, Not Just Defense
This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.
Chart of the Day: UNH's Universal Healthcare Comments Sting Sector
The free press that the progressive push for Medicare got on Tuesday morning is hurting the healthcare sector.
Political Environment Pressures UnitedHealth Shares
UNH's operational strength can't overcome the potential political overhang at the moment.